modelNitrofurantoin

Diagram of Nitrofurantoin

Extends from Pharmacolibrary.Drugs.ATC.J.J01XE01.

Information

name:Nitrofurantoin
ATC code:J01XE01
route:oral
compartments:1
dosage:100mg
volume of distribution:0.8L
clearance:65mL/min
other parameters in model implementation

Nitrofurantoin is an antibacterial agent used primarily for the treatment and prophylaxis of urinary tract infections (UTIs). It is effective mainly against Escherichia coli and some other Gram-negative and Gram-positive bacteria. It is approved and widely used today for uncomplicated UTIs, particularly in women.

Pharmacokinetics

Pharmacokinetic parameters reported for healthy adult volunteers (both sexes) after oral administration of nitrofurantoin macrocrystals.

References

  1. Adkison, KK, et al., & Lee, EJ (2008). The ABCG2 C421A polymorphism does not affect oral nitrofurantoin pharmacokinetics in healthy Chinese male subjects. British journal of clinical pharmacology 66(2) 233–239. DOI:10.1111/j.1365-2125.2008.03184.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/18429968

  2. Wijma, RA, et al., & Muller, AE (2018). Review of the pharmacokinetic properties of nitrofurantoin and nitroxoline. The Journal of antimicrobial chemotherapy 73(11) 2916–2926. DOI:10.1093/jac/dky255 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30184207

  3. Zayyad, H, et al., & Paul, M (2017). Revival of old antibiotics: needs, the state of evidence and expectations. International journal of antimicrobial agents 49(5) 536–541. DOI:10.1016/j.ijantimicag.2016.11.021 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28162982

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.TransferRateka (from PK_1C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_1C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)